Abstract

UTILIZATION OF NOVEL DRUG DELIVERY SYSTEM IN THE PHARMACOTHERAPY OF HYPERLIPIDEMIA

Bharti*, Dr. Vinay Pandit and Dr. M. S. Ashawat

ABSTRACT

Hyperlipidemia is a raised state of lipid levels in the body and is known to accelerate an interaction of atherosclerosis that may demonstrate lethal in the improvement of different cardiovascular Disease. Increase in the lipids like LDL i.e low density lipoproteins, triglycerides and cholesterol are mainly responsible for hyperlipidemia. Present pharmacotherapy for hyperlipidemia includes statins or cholesterol absorption inhibitors. 90% of the pharmacotherapy of hyperlipidemia incorporates statins and these statins additionally suffer from limitations like, deficient solubility, less absorption, less bioavailability and incapability in bringing down of cholesterol levels only upto maximum 40% risk reduction. Statins are to be given on consistent schedule which make it lumbering for patients. Novel Drug Delivery System is a advanced drug delivery system with improved solublity, retention, bioavailability, drug power, control drug delivery to give a sustained therapeutic effect, and target arranged to an ideal tissue just as tolerant consistence is acceptable. So it is the need of hour to plan such kind of drug delivery system which will battle the limits of antihyperlipidemic treatment. The current review emphasise on utilizations of novel drug delivery system in pharmacotherapy of antihyperlipidemic drugs.

Keywords: Hyperlipidemia, Pharmacotherapy, Novel drug delivery system, Bioavailability, Statins.